On Jun. 15, 2020, Catalent announced that it will provide vial filling and packaging capacity to AstraZeneca at Catalentﾒs manufacturing facility in Anagni, Italy, and prepare for large-scale commercial supply of the University of Oxfordﾒs adenovirus vector based COVID-19 vaccine candidate, AZD1222.